Overview

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Status:
Completed

Trial end date:
2018-05-18

Target enrollment:

Participant gender:

Summary

The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and renal impairment (CKD). The study is planned to randomize a total of 450 patients (150 patients per treatment arm)

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dapagliflozin
Saxagliptin